Abstract:BACKGROUND:Lung cancers develop via multiple genetic and epigenetic changes, including inactivation of tumor suppressor genes. We previously cloned human G protein-coupled receptor family C type 5A (GPRC5A), whose expression is suppressed in some human lung carcinoma cells, and its mouse homolog Gprc5a.METHODS:We generated Gprc5a knockout mice by homologous recombination and studied their phenotype by macroscopic observation and microscopic histologic analysis of embryos and lungs of 1- to 2-year-old mice. GPRC5A mRNA expression was analyzed by reverse transcription-polymerase chain reaction in surgical specimens of 18 human lung tumors and adjacent normal tissues and by analyzing previously published data from 186 lung tumor tissues of a variety of histologic types and 17 normal lung samples. Human embryonic kidney, human non-small-cell lung cancer, and mouse lung adenocarcinoma cells were transfected with a GPRC5A expression vector or a control vector, and colony formation in semisolid medium was assayed. Statistical tests were two-sided.RESULTS:Homozygous knockout mice developed many more lung tumors at 1-2 years of age (incidence: 76% adenomas and 17% adenocarcinomas) than heterozygous (11% adenomas) or wild-type (10% adenomas) mice. Human GPRC5A mRNA levels were lower in most (11 of 18 [61%]) human lung tumors than in adjacent normal tissues. The mean GPRC5A mRNA level in adenocarcinoma (n = 139), squamous cell carcinoma (n = 21), small-cell lung cancer (n = 6), and carcinoid (n = 20) tissues was 46.2% (P = .014), 7.5% (P<.001), 5.3% (P<.001), and 1.8% (P<.001), respectively, that in normal lung tissues (n = 17) GPRC5A transfection suppressed colony formation in semisolid medium of immortalized human embryonic kidney, human non-small-cell lung cancer, and mouse lung adenocarcinoma cells by 91%, 91%, and 68%, respectively, compared with vector controls (all P<.001).CONCLUSIONS:Gprc5a functions as a tumor suppressor in mouse lung, and human GPRC5A may share this property. The Gprc5a-deficient mouse is a novel model to study lung carcinogenesis and chemoprevention.

[Expression of Tumor Suppressor Gene PRDM1 in Lung Cancers].

[Expression of Human Testis Development Related Gene 1 in Testicular Cancer Detected by Tissue Microarray].

High expression of PRDM14 correlates with cell differentiation and is a novel prognostic marker in resected non-small cell lung cancer

The Epigenetic Modifier PRDM5 Functions As a Tumor Suppressor Through Modulating WNT/β-catenin Signaling and is Frequently Silenced in Multiple Tumors.

Identification of Preferentially Expressed Antigen of Melanoma As a Potential Tumor Suppressor in Lung Adenocarcinoma

Clinical significance of PRDM1 gene expression in laryngeal squamous cell carcinoma

Role of PRDM1 in Tumor Immunity and Drug Response: A Pan-Cancer Analysis

Promoter Methylation-Mediated Downregulation of PRDM5 Contributes to the Development of Lung Squamous Cell Carcinoma.

Expression of PTEN protein in primary lung cancer

Analysis of BRG1 Expression in Primary Lung Cancers and Multiple Tumor Cell Lines

Protein Regulator of Cytokinesis-1 Expression: Prognostic Value in Lung Squamous Cell Carcinoma Patients.

Induction of tumor inhibition and apoptosis by a candidate tumor suppressor gene DRR1 on 3p21.1.

Identification and Expression Analysis of PRM1 as a Novel Candidate Cancer/Testis Gene in Human Colorectal Cancer

PRDM1 expression and prognostic value in patients with diffuse large B-cell lymphoma

Deregulation of PRDM5 promotes cell proliferation by regulating JAK/STAT signaling pathway through SOCS1 in human lung adenocarcinoma

Identification of the Retinoic Acid-Inducible Gprc5a As a New Lung Tumor Suppressor Gene.

Preliminary Study on the Cause of BRG1 Down-Expression in Primary Lung Cancers and Multiple Tumor Cell Lines

Expression of DNA Methyltransferase 1(dnmt1)in Lung Adenocarcinoma and Its Prognostic Significance

Expression of PTEN DNA in primary lung carcinoma by in situ PCR

A Potential Prognostic Marker PRDM1 in Pancreatic Adenocarcinoma

GPRC5A Deficiency Leads to Dysregulated MDM2 Via Activated EGFR Signaling for Lung Tumor Development